AUG 10, 2026 · PHASE 3 TRIAL
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
ClinicalTrials.gov
This is a recruiting Phase 3 trial registration with no results posted; the study design is rigorous but outcomes are not yet reported, making it a planned intervention study only.
Reported
Planned sample size220
Primary endpointDistant metastasis free survival (DMFS)
Primary outcome timing6.25 years after first patient randomised